Taichung Veterans General Hospital
Ultralow-dose interferon plus ribavirin helps HCV-positive kidney recipients
Published in MD Week, September 3rd, 2004
According to recent research published in the journal Transplantation, "interferon treatment of hepatitis C virus (HCV) infection in transplant recipients carries a high risk of rejection. We treated these patients with ultralow-dose interferon-alpha (1x106 units subcutaneously three times/week) plus ribavirin (600 mg/day) for 48 weeks. Treatment efficacy was evaluated by the changes of serum liver enzymes and viral load."
"A total of 11 patients were recruited for the study; biochemical response was obtained in all patients but 1. Three patients...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of MD Week
Source: MD Week (2004-09-03)
More Articles from MD Week
- Business & Finance
Fitch releases 2004 median ratios for U.S. nonprofit hospitals - Finance
Home health nursing company reports income of $0.39 per share - Finance
NDCHealth swings to quarterly loss - Finance
Survey explores retirement plan trends in U.S. healthcare market - Healthcare Coverage
Study shows Medicaid, states' big cost, is politically untouchable - Cedars-Sinai Medical Center
Immune vaccine followed by chemotherapy slows incurable brain tumors - More from this issue of MD Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
